Towards a Brucella vaccine for humans.

There is currently no licensed vaccine for brucellosis in humans. Available animal vaccines may cause disease and are considered unsuitable for use in humans. However, the causative pathogen, Brucella, is among the most common causes of laboratory-acquired infections and is a Center for Disease Control category B select agent. Thus, human vaccines for brucellosis are required. This review highlights the considerations that are needed in the journey to develop a human vaccine, including animal models, and includes an assessment of the current status of novel vaccine candidates.

[1]  I. F. Huddleson,et al.  The Pathogenicity of the Species of the Genus Brucella for Monkeys. , 1929 .

[2]  S. Elberg,et al.  Respiratory pathogenicity of Brucella. , 1948, The Journal of infectious diseases.

[3]  A. Braude,et al.  Studies in the pathology and pathogenesis of experimental brucellosis. I. A comparison of the pathogenicity of Brucella abortus, Brucella melitensis, and Brucella suis for guinea pigs. , 1951, The Journal of infectious diseases.

[4]  S. Elberg,et al.  Immunization against brucella infection. I. Isolation and characterization of a streptomycin-dependent mutant. , 1953, Journal of bacteriology.

[5]  K. F. Meyer,et al.  IMMUNIZATION AGAINST BRUCELLA INFECTION II , 1953, Journal of bacteriology.

[6]  Vershilova Pa.  The use of live vaccine for vaccination of human beings against brucellosis in the USSR. , 1961 .

[7]  P. Vershilova.  The use of live vaccine for vaccination of human beings against brucellosis in the USSR. , 1961, Bulletin of the World Health Organization.

[8]  James W. Hall,et al.  Immunization with viable Brucella organisms. Results of a safety test in humans. , 1962, Bulletin of the World Health Organization.

[9]  G. Rasooly,et al.  Immunization against Brucella with killed vaccines. Immunizing activity in mice of Brucella cell walls and of fractions derived from them. , 1966, Israel journal of medical sciences.

[10]  R. Sidwell,et al.  Experimental studies with four species of Brucella in selected wildlife, laboratory, and domestic animals. , 1967, The American journal of tropical medicine and hygiene.

[11]  G. Rasooly,et al.  Immunization against Brucella with killed baccines. 3. Experiments in mice. , 1968, Israel journal of medical sciences.

[12]  D. Percy,et al.  Experimental Brucella canis infection in the monkey (Macaca arctoides). , 1972, Canadian journal of comparative medicine : Revue canadienne de medecine comparee.

[13]  G. Renoux,et al.  Phenol-water fractions from smooth Brucella abortus and Brucella melitensis: immunochemical analysis and biologic behavior. , 1973, The Journal of infectious diseases.

[14]  J. Roux,et al.  Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances , 1976, Infection and immunity.

[15]  A. Kaufmann,et al.  AIRBORNE SPREAD OF BRUCELLOSIS , 1980, Annals of the New York Academy of Sciences.

[16]  M. Hogarth,et al.  In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection. , 1982, Cellular immunology.

[17]  Meador Vp,et al.  Experimentally induced Brucella abortus infection in pregnant goats. , 1986 .

[18]  A. M. Wu,et al.  Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies , 1986, Infection and immunity.

[19]  B. L. Deyoe,et al.  Experimentally induced Brucella abortus infection in pregnant goats. , 1986, American journal of veterinary research.

[20]  P. Elzer,et al.  Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. , 1989, Journal of immunology.

[21]  L. G. Adams,et al.  Capacity of passively administered antibody to prevent establishment of Brucella abortus infection in mice , 1989, Infection and immunity.

[22]  B. L. Deyoe,et al.  Protection of mice against Brucella abortus infection by inoculation with monoclonal antibodies recognizing Brucella O-antigen. , 1989, American journal of veterinary research.

[23]  J. D. Colmenero Castillo,et al.  Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. , 1989, Chemotherapy.

[24]  M. Miravitlles,et al.  Treatment of Human Brucellosis with Doxycycline plus Rifampin or Doxycycline plus Streptomycin , 1992, Annals of Internal Medicine.

[25]  R. Gerli,et al.  Lymphocytes bearing the gamma delta T cell receptor in acute Brucella melitensis infection. , 1993, European journal of immunology.

[26]  J. Montejo,et al.  Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Blasco,et al.  Evaluation of vaccines and of antigen therapy in a mouse model for Brucella ovis. , 1993, Vaccine.

[28]  R. Gerli,et al.  Lymphocytes bearing the γδ T cell receptor in acute Brucella melitensis infection , 1993 .

[29]  W. G. Miller,et al.  Characteristics of a Brucella Species from a Bottlenose Dolphin (Tursiops Truncatus) , 1994, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[30]  P. Elzer,et al.  BALB/c mice infected with Brucella abortus express protracted polyclonal responses of both IgG2a and IgG3 isotypes. , 1994, Immunology letters.

[31]  G. Splitter,et al.  CD8+ Type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I‐ and class II‐deficient mice , 1995, European journal of immunology.

[32]  E. M. Hoffmann,et al.  Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. , 1995, Critical reviews in microbiology.

[33]  C. Baldwin,et al.  Interleukin-10 downregulates protective immunity to Brucella abortus , 1995, Infection and immunity.

[34]  G. Splitter,et al.  RecombinantBrucella abortusProteins That Induce Proliferation and Gamma-Interferon Secretion by CD4+T Cells fromBrucella-Vaccinated Mice and Delayed-Type Hypersensitivity in Sensitized Guinea Pigs , 1996 .

[35]  G. Splitter,et al.  Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. , 1996, Vaccine.

[36]  P. Thompson,et al.  Brucella species infection in North Sea seal and cetacean populations , 1996, Veterinary Record.

[37]  D. Fuller,et al.  Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization , 1996 .

[38]  Zhanqi Liu,et al.  Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms , 1996, Infection and immunity.

[39]  J. Dubuisson,et al.  Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode , 1997, Journal of virology.

[40]  M. Palmer,et al.  Effects of oral or intravenous inoculation with Brucella abortus strain RB51 vaccine in beagles. , 1997, American journal of veterinary research.

[41]  G. Splitter,et al.  Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. , 1997, Vaccine.

[42]  R. Vemulapalli,et al.  Cloning and Sequencing of yajC and secDHomologs of Brucella abortus and Demonstration of Immune Responses to YajC in Mice Vaccinated with B. abortus RB51 , 1998, Infection and Immunity.

[43]  T. Ficht,et al.  Transposon-Derived Brucella abortusRough Mutants Are Attenuated and Exhibit Reduced Intracellular Survival , 1998, Infection and Immunity.

[44]  M. Castillejos,et al.  Multivariate model for predicting relapse in human brucellosis. , 1998, The Journal of infection.

[45]  C. Cheers,et al.  Control of IL-12 and IFN-gamma production in response to live or dead bacteria by TNF and other factors. , 1998, Journal of immunology.

[46]  R. Vemulapalli,et al.  Vaccination with Live Escherichia coli ExpressingBrucella abortus Cu/Zn Superoxide Dismutase Protects Mice against Virulent B. abortus , 1999, Infection and Immunity.

[47]  S. Henri,et al.  Identification of a candidate vaccine peptide on the 37 kDa Schistosoma mansoni GAPDH. , 2000, Vaccine.

[48]  J. Blasco,et al.  In vitro markers and biological activity in mice of seed lot strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. , 2000, Biologicals : journal of the International Association of Biological Standardization.

[49]  E. Andrews,et al.  Identification and partial characterisation of a new protective antigen of Brucella abortus. , 2000, Journal of medical microbiology.

[50]  G. Schurig,et al.  Humoral immune response of BALB/c mice to a vaccinia virus recombinant expressing Brucella abortus GroEL does not correlate with protection against a B. abortus challenge. , 2000, Veterinary microbiology.

[51]  T. Ficht,et al.  Identification of Genes Required for Chronic Persistence of Brucella abortus in Mice , 2000, Infection and Immunity.

[52]  T. Hadfield,et al.  Impaired Control of Brucella melitensisInfection in Rag1-Deficient Mice , 2000, Infection and Immunity.

[53]  C. Baldwin,et al.  Interferon‐γ is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice , 2001, Immunology.

[54]  J. Letesson,et al.  Protection of BALB/c Mice against Brucella abortus 544 Challenge by Vaccination with Bacterioferritin or P39 Recombinant Proteins with CpG Oligodeoxynucleotides as Adjuvant , 2001, Infection and Immunity.

[55]  T. Hadfield,et al.  Bacteriologic and histologic features in mice after intranasal inoculation of Brucella melitensis. , 2001, American journal of veterinary research.

[56]  M. Bronze,et al.  Bacterial Pathogens as Biological Weapons and Agents of Bioterrorism , 2002, The American journal of the medical sciences.

[57]  D. Fuller,et al.  Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma. , 2002, Current opinion in molecular therapeutics.

[58]  V. DelVecchio,et al.  Characterization of the caprine model for ruminant brucellosis. , 2002, Veterinary microbiology.

[59]  V. Azevedo,et al.  Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation. , 2002, Journal of medical microbiology.

[60]  V. Azevedo,et al.  Induction of a th1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene. , 2002, Journal of medical microbiology.

[61]  J. Letesson,et al.  Yersinia enterocolitica as a Vehicle for a Naked DNA Vaccine Encoding Brucella abortus Bacterioferritin or P39 Antigen , 2002, Infection and Immunity.

[62]  J. Oliaro,et al.  The innate immune response against Brucella in humans. , 2002, Veterinary microbiology.

[63]  L. Capasso,et al.  Bacteria in two-millennia-old cheese, and related epizoonoses in Roman populations. , 2002, The Journal of infection.

[64]  G. Splitter,et al.  Virulence Criteria for Brucella abortus Strains as Determined by Interferon Regulatory Factor 1-Deficient Mice , 2002, Infection and Immunity.

[65]  M. Spitz,et al.  A DNA Vaccine Encoding Lumazine Synthase from Brucella abortus Induces Protective Immunity in BALB/c Mice , 2002, Infection and Immunity.

[66]  Mary S. Wu,et al.  Induction of Mucosal Protection against Primary, Heterologous Simian Immunodeficiency Virus by a DNA Vaccine , 2002, Journal of Virology.

[67]  Mice immune responses to Brucella abortus heat shock proteins. Use of baculovirus recombinant-expressing whole insect cells, purified Brucella abortus recombinant proteins, and a vaccinia virus recombinant as immunogens. , 2002, Veterinary microbiology.

[68]  T. Ficht.  Discovery of Brucella virulence mechanisms using mutational analysis. , 2002, Veterinary microbiology.

[69]  K. Hamajima,et al.  Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. , 2003, Blood.

[70]  G. Atkins,et al.  Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  E. Andrews,et al.  A DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus Induces Protective Immunity in BALB/c Mice , 2003, Infection and Immunity.

[72]  F. Goldbaum,et al.  Brucella Lumazine Synthase Elicits a Mixed Th1-Th2 Immune Response and Reduces Infection in Mice Challenged with Brucella abortus 544 Independently of the Adjuvant Formulation Used , 2003, Infection and Immunity.

[73]  B. Wallace,et al.  Laboratory-acquired Brucellosis , 2004, Emerging infectious diseases.

[74]  D. Hoover,et al.  Pathologic changes associated with brucellosis experimentally induced by aerosol exposure in rhesus macaques (Macaca mulatta). , 2004, American journal of veterinary research.

[75]  Gustavo Moraga-Cid,et al.  Intraspleen Delivery of a DNA Vaccine Coding for Superoxide Dismutase (SOD) of Brucella abortus Induces SOD-Specific CD4+ and CD8+ T Cells , 2004, Infection and Immunity.

[76]  D. Montefiori,et al.  Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen , 2004, AIDS.

[77]  I. Kakoma,et al.  Evaluation of the Sprague-Dawley rat as a model for vertical transmission of Brucella abortus. , 2005, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[78]  S. Rabot,et al.  A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors , 2005, The Journal of Immunology.

[79]  G. Donoso,et al.  An RNA Vaccine Based on Recombinant Semliki Forest Virus Particles Expressing the Cu,Zn Superoxide Dismutase Protein of Brucella abortus Induces Protective Immunity in BALB/c Mice , 2005, Infection and Immunity.

[80]  G. Splitter,et al.  Unraveling Brucella Genomics and Pathogenesis in Immunocompromised IRF‐1−/− Mice , 2005, American journal of reproductive immunology.

[81]  V. Lafont,et al.  Vγ9Vδ2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria Brucella , 2005 .

[82]  S. Estein,et al.  A DNA Vaccine Coding for the Brucella Outer Membrane Protein 31 Confers Protection against B. melitensis and B. ovis Infection by Eliciting a Specific Cytotoxic Response , 2005, Infection and Immunity.

[83]  Tolerance of the human brucellosis vaccine and the intradermal reaction test for brucellosis , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[84]  R. Vemulapalli,et al.  Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein. , 2005, Veterinary microbiology.

[85]  S. Estein,et al.  Vaccination with the Recombinant Brucella Outer Membrane Protein 31 or a Derived 27-Amino-Acid Synthetic Peptide Elicits a CD4+ T Helper 1 Response That Protects against Brucella melitensis Infection , 2005, Infection and Immunity.

[86]  H. Flick-Smith,et al.  Human Immune Response to a Plague Vaccine Comprising Recombinant F1 and V Antigens , 2005, Infection and Immunity.

[87]  Xinghong Yang,et al.  Selection of Protective Epitopes for Brucella melitensis by DNA Vaccination , 2005, Infection and Immunity.

[88]  R. Vemulapalli,et al.  Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2. , 2006, Immunobiology.

[89]  P. Li,et al.  Protective Immunity Elicited by a Divalent DNA Vaccine Encoding Both the L7/L12 and Omp16 Genes of Brucella abortus in BALB/c Mice , 2006, Infection and Immunity.

[90]  S. Perkins,et al.  Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. , 2006, Vaccine.

[91]  J. Haynes,et al.  Epidermal DNA vaccine for influenza is immunogenic in humans. , 2006, Vaccine.

[92]  F. Goldbaum,et al.  Brucella outer membrane protein Omp31 is a haemin-binding protein. , 2006, Microbes and infection.

[93]  P. Li,et al.  DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. , 2006, Chinese medical journal.

[94]  E. Andrews,et al.  Vaccination with Live Escherichia coli Expressing Brucella abortus Cu/Zn Superoxide‐Dismutase , 2006, Microbiology and immunology.

[95]  Y. Le Loir,et al.  Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis , 2006, Microbial cell factories.

[96]  C. Seabury,et al.  Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. , 2006, Vaccine.

[97]  Yi-jing Li,et al.  [Progress on lactococcus lactis expressing heterologous antigens as live mucosal vaccines]. , 2006, Wei sheng wu xue bao = Acta microbiologica Sinica.

[98]  H. Cai,et al.  A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. , 2007, DNA and cell biology.

[99]  D. Doolan,et al.  Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. , 2007, Immunology letters.

[100]  Xinghong Yang,et al.  Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. , 2007, Vaccine.

[101]  C. Mervis,et al.  Rearrangements of the Williams–Beuren syndrome locus: molecular basis and implications for speech and language development , 2007, Expert Reviews in Molecular Medicine.

[102]  B. Wren,et al.  The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. , 2007, Vaccine.

[103]  D. Zelterman,et al.  Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. , 2007, Vaccine.

[104]  S. Estein,et al.  Improved Immunogenicity of a Vaccination Regimen Combining a DNA Vaccine Encoding Brucella melitensis Outer Membrane Protein 31 (Omp31) and Recombinant Omp31 Boosting , 2007, Clinical and Vaccine Immunology.

[105]  T. Ficht,et al.  Aerosol Infection of BALB/c Mice with Brucella melitensis and Brucella abortus and Protective Efficacy against Aerosol Challenge , 2007, Infection and Immunity.

[106]  S. Olsen,et al.  An Aerosolized Brucella spp. Challenge Model for Laboratory Animals , 2007, Zoonoses and public health.

[107]  M. A. Ansari,et al.  Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. , 2007, Vaccine.

[108]  M. Imperiale,et al.  Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[109]  M. Delpino,et al.  Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. , 2007, Vaccine.

[110]  D. Laplagne,et al.  A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. , 2007, Vaccine.

[111]  D. Laplagne,et al.  A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. , 2007, Vaccine.

[112]  J. Gorvel,et al.  Virulence factors in brucellosis: implications for aetiopathogenesis and treatment , 2007, Expert Reviews in Molecular Medicine.

[113]  T. Ficht,et al.  Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection against Wild-Type Challenge , 2008, Infection and Immunity.

[114]  Sandra K. Martin,et al.  Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. , 2008, JAMA.

[115]  Z. Hubálek,et al.  Brucella microti sp. nov., isolated from the common vole Microtus arvalis. , 2008, International journal of systematic and evolutionary microbiology.

[116]  E. Andrews,et al.  Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu-Zn superoxide dismutase (SOD) gene in cattle. , 2008, Veterinary microbiology.

[117]  T. Ficht,et al.  The Brucella abortus S19 ΔvjbR Live Vaccine Candidate Is Safer than S19 and Confers Protection against Wild-Type Challenge in BALB/c Mice When Delivered in a Sustained-Release Vehicle , 2008, Infection and Immunity.

[118]  O. Zhirnov,et al.  Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. , 2008, Vaccine.

[119]  S. Estein,et al.  Immunization with Recombinant Brucella Species Outer Membrane Protein Omp16 or Omp19 in Adjuvant Induces Specific CD4+ and CD8+ T Cells as Well as Systemic and Oral Protection against Brucella abortus Infection , 2008, Infection and Immunity.

[120]  S. Srivastava,et al.  Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus. , 2008, Microbes and infection.

[121]  J. Al-Tawfiq.  Therapeutic options for human brucellosis , 2008, Expert review of anti-infective therapy.

[122]  H. Atkins,et al.  Development and Characterization of Mouse Models of Infection with Aerosolized Brucella melitensis and Brucella suis , 2009, Clinical and Vaccine Immunology.

[123]  P. Nathanielsz,et al.  A novel Brucella isolate in association with two cases of stillbirth in non‐human primates – first report , 2009, Journal of medical primatology.

[124]  G. Vergnaud,et al.  Brucella inopinata sp. nov., isolated from a breast implant infection. , 2010, International journal of systematic and evolutionary microbiology.